Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck's Keytruda Claims Market Leadership In First-line Lung Cancer

Executive Summary

Merck enjoyed a good second quarter, beating sales expectations for Keytruda and other drugs, which helped offset losses related to patent expirations.

Advertisement

Related Content

Merck To Build Case For Doravirine-Based HIV Products On Efficacy, Safety Differences
Merck's Keytruda Enjoys Clean Sweep In Lung Cancer, At Bristol's Expense
Bristol Debuts Opdivo/Yervoy Data In New First-Line Lung Cancer Bid
Pharma Q3 Results Preview: Merck & Co., Merck KGaA
Post-MYSTIC, Bristol Renews CTLA-4 Vows, But Is "Not Wedded" In Lung Cancer
A Whopper Of A Deal: AZ Hands Half Of Lynparza To Merck
MYSTIC Misses: Devastation For AstraZeneca As Imfinzi Fails PFS Endpoint In NSCLC
Merck's Keytruda Gets Benefit Of Doubt, Despite Failing in Head & Neck
FDA Clinical Hold Hits Keytruda Multiple Myeloma Studies
Big REVEAL: Merck's Anacetrapib Surprises With Success, But What Next?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099230

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel